<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.hcplive.com/view/upadacitinib-response-within-days-in-crohn-s-disease-with-raja-atreya-md</loc>
      <lastmod>2026-11-17T17:00:19.905Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:00:19.905Z</news:publication_date>
        <news:title><![CDATA[Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/dont-miss-a-beat-how-prediction-markets-could-threaten-clinical-trial-integrity</loc>
      <lastmod>2026-11-17T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:00:00Z</news:publication_date>
        <news:title><![CDATA[Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial Integrity]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/asundexian-s-fda-approval-opens-doors-for-future-antithrombotic-therapies</loc>
      <lastmod>2026-11-16T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Asundexian’s FDA Approval Opens Doors for Future Antithrombotic Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/diabetes-dialogue-optimal-diabetes-survodutide-and-orforglipron-at-aha-2026</loc>
      <lastmod>2026-11-16T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/diabetes-dialogue-tubeless-mobi-clearance-cgm-choice-and-eversense-freedom</loc>
      <lastmod>2026-11-16T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense Freedom]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/microbiome-therapies-show-potential-in-hepatic-encephalopathy</loc>
      <lastmod>2026-11-16T16:56:41.331Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:56:41.331Z</news:publication_date>
        <news:title><![CDATA[Microbiome Therapies Show Potential in Hepatic Encephalopathy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/treatment-gaps-persist-in-hepatic-encephalopathy-despite-standard-care</loc>
      <lastmod>2026-11-16T16:56:41.331Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:56:41.331Z</news:publication_date>
        <news:title><![CDATA[Treatment Gaps Persist in Hepatic Encephalopathy Despite Standard Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/remibrutinib-cindu-responses-week-52-giselle-mosnaim-md</loc>
      <lastmod>2026-11-16T16:43:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:43:00Z</news:publication_date>
        <news:title><![CDATA[Remibrutinib Sustains CIndU Responses at Week 52, with Giselle Mosnaim, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/the-future-of-igan-care-personalized-goals-and-practice-changing-steps</loc>
      <lastmod>2026-11-16T16:07:07.395Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:07:07.395Z</news:publication_date>
        <news:title><![CDATA[The Future of IgAN Care: Personalized Goals and Practice-Changing Steps]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/emerging-b-cell-therapies-and-real-world-evidence-in-igan</loc>
      <lastmod>2026-11-16T16:07:05.794Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:07:05.794Z</news:publication_date>
        <news:title><![CDATA[Emerging B-Cell Therapies and Real-World Evidence in IgAN]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/choosing-and-sequencing-igan-therapies-oral-agents-biologics-and-combinations</loc>
      <lastmod>2026-11-16T16:07:04.243Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:07:04.243Z</news:publication_date>
        <news:title><![CDATA[Choosing and Sequencing IgAN Therapies: Oral Agents, Biologics, and Combinations]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/b-cell-biologic-safety-in-igan-monitoring-and-patient-selection</loc>
      <lastmod>2026-11-16T16:07:02.402Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:07:02.402Z</news:publication_date>
        <news:title><![CDATA[B-Cell Biologic Safety in IgAN: Monitoring and Patient Selection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/dual-baff-april-inhibition-in-igan-origin-3-data-and-open-questions</loc>
      <lastmod>2026-11-16T16:07:00.548Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:07:00.548Z</news:publication_date>
        <news:title><![CDATA[Dual BAFF/APRIL Inhibition in IgAN: ORIGIN 3 Data and Open Questions]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-updates-aficamten-label-with-maple-hcm-data-in-obstructive-hcm</loc>
      <lastmod>2026-11-16T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:30:00Z</news:publication_date>
        <news:title><![CDATA[FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/fda-approves-dexmedetomidine-home-schizophrenia-bipolar-agitation</loc>
      <lastmod>2026-11-16T14:28:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T14:28:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Dexmedetomidine for At-Home Schizophrenia, Bipolar Agitation]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/next-generation-tyk2-inhibitors-and-speed-of-response-in-pso</loc>
      <lastmod>2026-11-16T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Next-Generation TYK2 Inhibitors and Speed of Response in PsO]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/high-impact-site-clearance-and-durability-with-oral-il-23-inhibition-in-pso</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[High-Impact Site Clearance and Durability With Oral IL-23 Inhibition in PsO]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/allergic-reactions-do-not-blunt-sublingual-epinephrine-lieberman</loc>
      <lastmod>2026-11-16T12:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Allergic Reactions Do Not Blunt Sublingual Epinephrine: Jay Lieberman, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/navenibart-cuts-hae-attacks-90-percent-banerji</loc>
      <lastmod>2026-11-16T04:30:49.678Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T04:30:49.678Z</news:publication_date>
        <news:title><![CDATA[Navenibart Cuts HAE Attacks by 90% or More: Aleena Banerji, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/mid-pregnancy-pm2-5-exposure-tied-childhood-asthma-wildfire-regions</loc>
      <lastmod>2026-11-16T00:58:47.210Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T00:58:47.210Z</news:publication_date>
        <news:title><![CDATA[Mid-Pregnancy PM2.5 Exposure Tied to Childhood Asthma in Wildfire Regions]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/data-safety-monitoring-boards-and-the-case-for-publishing-negative-results</loc>
      <lastmod>2026-11-15T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Data Safety Monitoring Boards and the Case for Publishing Negative Results]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.hcplive.com/view/pediatric-hae-quality-life-tools-lumry</loc>
      <lastmod>2026-11-15T20:48:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>HCPLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T20:48:00Z</news:publication_date>
        <news:title><![CDATA[Pediatric HAE Quality-of-Life Tools Underused, With William Lumry, MD]]></news:title>
      </news:news>
	</url></urlset>